Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Dosing of Brentuximab Vedotin for MF, SS, and LyP
NCT03587844Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2018
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in mycosis fungoides (MF), Sézary syndrome (SS), lymphomatoid papulosis (LyP), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2018; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)lymphomatoid papulosis (LyP)
Beyond the preview
Go deeper on NCT03587844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587844.